Search Results - "Siragusa, S"

Changes in RDW according to prognostic predictors in newly diagnosed multiple myeloma by Carlisi, Melania, Presti, R. Lo, Plano, F., Mancuso, S., Siragusa, S., Caimi, G.

“…RDW is an erythrocyte index that increase in multiple myeloma, in which it appears to have an important role in predicting outcome. For this reason, we…”
Get full text

Acquired haemophilia in cancer: A systematic and critical literature review by Napolitano, M., Siragusa, S., Mancuso, S., Kessler, C. M.

“…Aim There is a paucity of data on the clinical presentation and management of cancer patients with acquired haemophilia (AH), we here report a systematic…”
Get full text

Synthesis of γ-Aminobutyric Acid by Lactic Acid Bacteria Isolated from a Variety of Italian Cheeses by SIRAGUSA, S, DE ANGELIS, M, DI CAGNO, R, RIZZELLO, C. G, CODA, R, GOBBETTI, M

“…Classifications Services AEM Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Bone damage after chemotherapy for lymphoma: a real-world experience by Mancuso, S, Scaturro, Dalila, Santoro, M, Di Gaetano, G, Vitagliani, F, Falco, V, Siragusa, S, Gonnelli, S, Mauro, G Letizia

“…Despite recent improvements in survival due to advances in treatment, the quality of life of patients with lymphoma may be compromised by the long-term…”
Get full text

Covid-19 in Philadelphia-negative myeloproliferative neoplasms: a GIMEMA survey on incidence, clinical management and vaccine by Breccia, M., Piciocchi, A., Messina, M., Soddu, S., De Stefano, V., Bellini, M., Iurlo, A., Martino, B., Siragusa, S., Albano, F., Mora, B., Fazi, P., Vignetti, M., Guglielmelli, P., Palandri, F.

Get full text

Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients by Caramazza, D, Begna, K H, Gangat, N, Vaidya, R, Siragusa, S, Van Dyke, D L, Hanson, C, Pardanani, A, Tefferi, A

“…We have previously identified sole +9, 13q- or 20q-, as ‘favorable’ and sole +8 or complex karyotype as ‘unfavorable’ cytogenetic abnormalities in primary…”
Get full text

Manufacture of Fior di Latte cheese by incorporation of probiotic lactobacilli by Minervini, F, Siragusa, S, Faccia, M, Dal Bello, F, Gobbetti, M, De Angelis, M

“…This work aimed to select heat-resistant probiotic lactobacilli to be added to Fior di Latte (high-moisture cow milk Mozzarella) cheese. First, 18 probiotic…”
Get more information

Long‐term outcomes of patients with cerebral vein thrombosis: a multicenter study by DENTALI, F., POLI, D., SCODITTI, U., MINNO, M. N. D. DI, STEFANO, V. D., SIRAGUSA, S., KOSTAL, M., PALARETI, G., SARTORI, M. T., GRANDONE, E., VEDOVATI, M. C., AGENO, W., Falanga, Anna, Lerede, Teresa, Bianchi, Marina, Testa, Sophie, Witt, Dan, McCool, Katie, Bucherini, Eugenio, Grifoni, Elisa, Coalizzo, Daniela, Benedetti, Raffaella, Marietta, Marco, Sessa, Maria, Guaschino, Clara, Minno, Giovanni, Tufano, Antonella, Barbar, Sofia, Malato, Alessandra, Pini, Mario, Castellini, Paola, Barco, Stefano, Barone, Marisa, Paciaroni, Maurizio, Alberti, Andrea, Agnelli, Giancarlo, Giorgi Pierfranceschi, Matteo, Dulicek, Petr, Silingardi, Mauro, Federica, Landini, Ghirarduzzi, Angelo, Tiraferri, Eros, Lazzaro, Vincenzo, Rossi, Elena, Ciminello, Angela, Pasca, Samantha, Barillari, Giovanni, Rezoagli, Emanuele, Galli, Matteo, Squizzato, Alessandro, Tosetto, Alberto

“…Background:  Little information is available on the long‐term clinical outcome of cerebral vein thrombosis (CVT). Objectives and methods:  In an international,…”
Get full text

Comparison between thrombotic risk scores in essential thrombocythemia and survival implications by Santoro, M., Accurso, V., Mancuso, S., Carlisi, M., Raso, S., Tarantino, G., Di Piazza, F., Perez, A., Russo, A., Siragusa, S.

“…The conventional thrombotic risk stratification in essential thrombocythemia (ET) distinguishes patients in two risk groups based on previous thrombosis and…”
Get full text

Clinical course of patients with symptomatic isolated superficial vein thrombosis: the ICARO follow‐up study by Barco, S., Pomero, F., Di Minno, M. N. D., Tamborini Permunian, E., Malato, A., Pasca, S., Barillari, G., Fenoglio, L., Siragusa, S., Di Minno, G., Ageno, W., Dentali, F.

“…Essentials Late sequelae of isolated superficial vein thrombosis (iSVT) have rarely been investigated. We studied 411 consecutive outpatients with acute iSVT…”
Get full text

Low dose of aPCC after the initial treatment in acquired haemophilia A is useful to reduce bleeding relapses: Data from the FAIR registry by Zanon, E., Pasca, S., Siragusa, S., Napolitano, M., Santoro, C., Mameli, L., Rocino, A.

“…Bypassing agents are the first line therapy in patients with acquired haemophilia A (AHA). Activated prothrombin complex concentrate (aPCC) proved to be…”
Get full text

Molecular and functional characterization of Lactobacillus sanfranciscensis strains isolated from sourdoughs by De Angelis, M., Di Cagno, R., Gallo, G., Curci, M., Siragusa, S., Crecchio, C., Parente, E., Gobbetti, M.

“…Fifty isolates of Lactobacillus sanfranciscensis from Italian sourdoughs were identified and typed by a polyphasic approach which included genotypic and…”
Get full text

Haemorheological profile in congenital afibrinogenemia and in congenital dysfibrinogenemia: A clinical case report by Caimi, G, Raso, S, Napolitano, M, Hopps, E, Lo Presti, R, Siragusa, S

“…Although the inherited quantitative and qualitative disorders of fibrinogen are rare, in the course of time patients may develop complications including…”
Get more information

Prognostic relevance of an asymptomatic venous thromboembolism in patients with cancer by DENTALI, F., AGENO, W., GIORGI PIERFRANCESCHI, M., IMBERTI, D., MALATO, A., NITTI, C., SALVI, A., SIRAGUSA, S., SQUIZZATO, A., VITALE, J., AGNELLI, G.

Get full text

Clinical experience with retrievable vena cava filters: results of a prospective observational multicenter study by IMBERTI, D., BIANCHI, M., FARINA, A., SIRAGUSA, S., SILINGARDI, M., AGENO, W.

“…Background: Retrievable inferior vena cava (IVC) filters offer the attractive possibility to be definitive or to be removed when they become unnecessary…”
Get full text

Combined use of antifibrinolytics and activated prothrombin complex concentrate (aPCC) is not related to thromboembolic events in patients with acquired haemophilia A: data from FAIR Registry by Pasca, S., Ambaglio, C., Rocino, A., Santoro, C., Cantori, I., Zanon, E.

“…Antifibrinolytics combined with aPCC are not routinely administered to patients with acquired hemophilia A due to increased thrombotic risk. This association…”
Get full text

IDH mutations and trisomy 8 in myelodysplastic syndromes and acute myeloid leukemia by Caramazza, D, Lasho, T L, Finke, C M, Gangat, N, Dingli, D, Knudson, R A, Siragusa, S, Hanson, C A, Pardanani, A, Ketterling, R P, Tefferi, A

Get full text

Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results by PENGO, V., CRIPPA, L., FALANGA, A., FINAZZI, G., MARONGIU, F., MOIA, M., PALARETI, G., POLI, D., TESTA, S., TIRAFERRI, E., TOSETTO, A., TRIPODI, A., SIRAGUSA, S., MANOTTI, C.

“…In this overview we address the three phase III studies that compared new oral anticoagulants (dabigatran, rivaroxaban and apixaban) with warfarin in the…”
Get full text

NADP-glutamate dehydrogenase activity in nonstarter lactic acid bacteria: effects of temperature, pH and NaCl on enzyme activity and expression by De Angelis, M, Calasso, M, Di Cagno, R, Siragusa, S, Minervini, F, Gobbetti, M

“…To screen the glutamate dehydrogenase (GDH) activity of nonstarter lactic acid bacteria (NSLAB) and to determine the effects of temperature, pH and NaCl values…”
Get full text

Patients requiring interruption of long‐term oral anticoagulant therapy: the use of fixed sub‐therapeutic doses of low‐molecular‐weight heparin by MALATO, A., SACCULLO, G., LO COCO, L., CARAMAZZA, D., ABBENE, I., PIZZO, G., CASUCCIO, A., SIRAGUSA, S.

“…Introduction: We tested the efficacy and safety of fixed doses of low‐molecular‐weight heparin (LMWH) in patients requiring interruption of vitamin‐K…”
Get full text